Skip to content
Screener

Haemonetics HAE Q4 2025 Annual earnings

Reported May 8, 2025 · Before market open

Revenue$330.6MBeat by $18.1M
EPS$1.24Beat by $0.02
Revenue estimate$312.5M
EPS estimate$1.22

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$345.0M
EPS estimate$1.30

Financials

Q4 2025

Income statement

See full
Revenue$330.6M-3.7%
Gross profit$193.1M+9.7%
Operating income$71.3M+138%
Net income$58.0M+185%
EPS (diluted)$1.17+192%

Balance sheet

See full
Cash & equivalents$306.8M+71.6%
Total debt$1.3B+46.9%
Total equity$820.8M-14.5%
Total assets$2.5B+11.6%

Cash flow

See full
Operating cash flow$116.6M+81.9%
CapEx$15.6M+134%
Free cash flow$100.9M+75.8%

Valuation & ratios

Valuation

as of 03/29/25
See full
Market cap$3.19B-26.3%
Enterprise value$4.17B-17.1%
P/E19×-17.8×
P/S2.3×-1.0×

Profitability

See full
Gross margin55%+2.2pp
Operating margin16.3%+3.7pp
Net margin12.3%+3.3pp
FCF margin10.5%—

Returns & leverage

See full
Return on equity18.8%+5.6pp
Debt / equity1.6×+0.7×
Current ratio1.6×-0.9×

Segments

By geography

See full
Other$2.8M-16.6%

By product

See full
Plasma$126.7M-9.1%

FAQ

When did Haemonetics report Q4 2025 earnings?
Haemonetics (HAE) reported Q4 2025 earnings on May 8, 2025 before market open.
What were Haemonetics's Q4 2025 revenue and EPS?
Haemonetics reported revenue of $330.6M and eps of $1.24 for Q4 2025.
Did Haemonetics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $312.5M by $18.1M. EPS beat the consensus estimate of $1.22 by $0.02.
How did Haemonetics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 3.7% from $343.3M a year earlier and eps grew 37.8% from $0.90.
Where can I find Haemonetics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0000313143-25-000021) and the 10-K periodic report (0000313143-25-000025) directly on SEC EDGAR. The filing index links above go to sec.gov.